

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely variable conditions, adverse event rates observed in clinical trials of a drug cannot be directly compared with rates of clinical trials of another drug and may not reflect the rates observed in practice.

Mantle Cell Lymphoma

The data described below reflect exposure to IMBRUVICA in a clinical trial (Study 1104) that included 111 patients with previously treated MCL treated with 560 mg daily with a median treatment duration of 8.3 months.

The most commonly occurring adverse reactions ($\geq 20\%$) were thrombocytopenia, diarrhea, neutropenia, anemia, fatigue, musculoskeletal pain, peripheral edema, upper respiratory tract infection, nausea, bruising, dyspnea, constipation, rash, abdominal pain, vomiting and decreased appetite (see Tables 1 and 2).

The most common Grade 3 or 4 non-hematological adverse reactions ($\geq 5\%$) were pneumonia, abdominal pain, atrial fibrillation, diarrhea, fatigue, and skin infections.

Fatal and serious cases of renal failure have occurred with IMBRUVICA therapy. Increases in creatinine 1.5 to 3 times the upper limit of normal occurred in 9% of patients.

Adverse reactions from the MCL trial (N=111) using single agent IMBRUVICA 560 mg daily occurring at a rate of $\geq 10\%$ are presented in Table 1.

Table 1: Non-Hematologic Adverse Reactions in $\geq 10\%$ of Patients with MCL (N=111)

Body System	Adverse Reaction	All Grades (%)	Grade 3 or 4 (%)
Gastrointestinal disorders	Diarrhea	51	5
	Nausea	31	0
	Constipation	25	0
	Abdominal pain	24	5
	Vomiting	23	0
	Stomatitis	17	1
	Dyspepsia	11	0
Infections and infestations	Upper respiratory tract infection	34	0
	Urinary tract infection	14	3
	Pneumonia	14	7
	Skin infections	14	5
	Sinusitis	13	1
General disorders and administration site conditions	Fatigue	41	5
	Peripheral edema	35	3
	Pyrexia	18	1
	Asthenia	14	3

Body System	Adverse Reaction	All Grades (%)	Grade 3 or 4 (%)
Respiratory, thoracic and mediastinal disorders	Cough	22	0
	Oropharyngeal pain	14	0
	Dyspnea	12	0
Musculoskeletal and connective tissue disorders	Musculoskeletal pain	25	6
	Arthralgia	24	0
	Muscle spasms	18	2
Nervous system disorders	Dizziness	20	0
	Headache	18	2
Metabolism and nutrition disorders	Decreased appetite	16	2
Neoplasms benign, malignant, unspecified	Second malignancies*	12*	0
Vascular disorders	Hypertension	16	8

*One patient death due to histiocytic sarcoma.

Table 4: Treatment-Emergent* Hematologic Laboratory Abnormalities in Patients with CLL/SLL (N=51) in Study 1102

	Percent of Patients (N=51)	
	All Grades (%)	Grade 3 or 4 (%)
Platelets Decreased	69	12
Neutrophils Decreased	53	26
Hemoglobin Decreased	43	0

* Based on laboratory measurements per IWCLL criteria and adverse reactions.

RESONATE

Adverse reactions and laboratory abnormalities described below in [Tables 5](#) and [6](#) reflect exposure to IMBRUVICA with a median duration of 8.6 months and exposure to ofatumumab with a median of 5.3 months in RESONATE in patients with previously treated CLL/SLL.

Table 6: Treatment-Emergent Hematologic Laboratory Abnormalities in Patients with CLL/SLL in RESONATE

	IMBRUVICA (N=195)		Ofatumumab (N=191)	
	All Grades (%)	Grade 3 or 4 (%)	All Grades (%)	Grade 3 or 4 (%)
Neutrophils Decreased	51	23	57	26
Platelets Decreased	52	5	45	10
Hemoglobin Decreased	36	0	21	0

RESONATE-2

Adverse reactions described below in Table 7 reflect exposure to IMBRUVICA with a median duration of 17.4 months. The median exposure to chlorambucil was 7.1 months in RESONATE-2.

Table 7: Adverse Reactions Reported in $\geq 10\%$ of Patients and at Least 2% Greater in the IMBRUVICA Treated Arm in Patients with CLL/SLL in RESONATE-2

Body System Adverse Reaction	IMBRUVICA (N=135)		Chlorambucil (N=132)	
	All Grades (%)	Grade 3 or 4 (%)	All Grades (%)	Grade 3 or 4 (%)
Gastrointestinal disorders				
Diarrhea	42	4	17	0
Stomatitis*	14	1	4	1
Musculoskeletal and connective tissue disorders				
Musculoskeletal pain*	36	4	20	0
Arthralgia	16	1	7	1
Muscle spasms	11	0	5	0
Eye Disorders				
Dry eye	17	0	5	0
Lacrimation increased	13	0	6	0
Vision blurred	13	0	8	0
Visual acuity reduced	11	0	2	0
Skin and subcutaneous tissue disorders				
Rash*	21	4	12	2
Bruising*	19	0	7	0
Infections and infestations				
Skin infection*	15	2	3	1
Pneumonia*	14	8	7	4

Musculoskeletal and connective tissue disorders				
Musculoskeletal pain*	29	2	20	0
Muscle spasms	12	<1	5	0
General disorders and administration site conditions				
Pyrexia	25	4	22	2
Vascular Disorders				
Hemorrhage*	19	2	9	1
Hypertension *	11	5	5	2
Infections and infestations				
Bronchitis	13	2	10	3
Skin infection*	10	3	6	2
Metabolism and nutrition disorders				
Hyperuricemia	10	2	6	0

The body system and individual ADR terms are sorted in descending frequency order in the IMBRUVICA arm.

* Includes multiple ADR terms

<1 used for frequency above 0 and below 0.5%

Atrial fibrillation of any grade occurred in 7% of patients treated with IMBRUVICA + BR and 2% of patients treated with placebo + BR. The frequency of Grade 3 and 4 atrial fibrillation was 3% in patients treated with IMBRUVICA + BR and 1% in patients treated with placebo +BR.

Waldenström's Macroglobulinemia and Marginal Zone Lymphoma

The data described below reflect exposure to IMBRUVICA in open-label clinical trials that included 63 patients with previously treated WM (Study 1118) and 63 patients with previously treated MZL (Study 1121).

The most commonly occurring adverse reactions in Studies 1118 and 1121 ($\geq 20\%$) were thrombocytopenia, diarrhea, neutropenia, fatigue, bruising, hemorrhage, anemia, rash, musculoskeletal pain, and nausea.

Nine percent of patients receiving IMBRUVICA across Studies 1118 and 1121 discontinued treatment due to adverse reactions. The most common adverse reactions leading to discontinuation were interstitial lung disease, diarrhea and rash. Adverse reactions leading to dose reduction occurred in 10% of patients.

Study 1118

Adverse reactions and laboratory abnormalities described below in [Tables 9](#) and [10](#) reflect exposure to IMBRUVICA with a median duration of 11.7 months in Study 1118.

Table 9: Non-Hematologic Adverse Reactions in $\geq 10\%$ in Patients with WM in Study 1118 (N=63)

Body System	Adverse Reaction	All Grades (%)	Grade 3 or 4 (%)
Gastrointestinal disorders	Diarrhea	37	0
	Nausea	21	0
	Stomatitis*	16	0
	Gastroesophageal reflux disease	13	0
Skin and subcutaneous tissue disorders	Rash*	22	0
	Bruising*	16	0
	Pruritus	11	0
General disorders and administrative site conditions	Fatigue	21	0
Musculoskeletal and connective tissue disorders	Muscle spasms	21	0
	Arthropathy	13	0
Infections and infestations	Upper respiratory tract infection	19	0
	Sinusitis	19	0
	Pneumonia*	14	6
	Skin infection*	14	2
Respiratory, thoracic and mediastinal disorders	Epistaxis	19	0
	Cough	13	0
Nervous system disorders	Dizziness	14	0
	Headache	13	0
Neoplasms benign, malignant, and unspecified (including cysts and polyps)	Skin cancer*	11	0

The body system and individual ADR preferred terms are sorted in descending frequency order.

* Includes multiple ADR terms.

Table 10: Treatment-Emergent Hematologic Laboratory Abnormalities in Patients with WM in Study 1118 (N=63)

	Percent of Patients (N=63)	
	All Grades (%)	Grade 3 or 4 (%)
Platelets Decreased	43	13
Neutrophils Decreased	44	19
Hemoglobin Decreased	13	8

- *Atrial fibrillation:*
Counsel patients to report any signs of palpitations, lightheadedness, dizziness, fainting, shortness of breath, and chest discomfort [see *Warnings and Precautions (5.4)*].
- *Hypertension:*
Inform patients that high blood pressure has occurred in patients taking IMBRUVICA, which may require treatment with anti-hypertensive therapy [see *Warnings and Precautions (5.5)*].
- *Second primary malignancies:*
Inform patients that other malignancies have occurred in patients who have been treated with IMBRUVICA, including skin cancers and other carcinomas [see *Warnings and Precautions (5.6)*].
- *Tumor lysis syndrome:*
Inform patients of the potential risk of tumor lysis syndrome and to report any signs and symptoms associated with this event to their healthcare provider for evaluation [see *Warnings and Precautions (5.7)*].
- *Embryo-fetal toxicity:*
Advise women of the potential hazard to a fetus and to avoid becoming pregnant during treatment and for 1 month after the last dose of IMBRUVICA [see *Warnings and Precautions (5.8)*].
- Inform patients to take IMBRUVICA orally once daily according to their physician's instructions and that the capsules should be swallowed whole with a glass of water without being opened, broken, or chewed at approximately the same time each day [see *Dosage and Administration (2.1)*].
- Advise patients that in the event of a missed daily dose of IMBRUVICA, it should be taken as soon as possible on the same day with a return to the normal schedule the following day. Patients should not take extra capsules to make up the missed dose [see *Dosage and Administration (2.6)*].
- Advise patients of the common side effects associated with IMBRUVICA [see *Adverse Reactions (6)*]. Direct the patient to a complete list of adverse drug reactions in PATIENT INFORMATION.
- Advise patients to inform their health care providers of all concomitant medications, including prescription medicines, over-the-counter drugs, vitamins, and herbal products [see *Drug Interactions (7)*].
- Advise patients that they may experience loose stools or diarrhea, and should contact their doctor if their diarrhea persists. Advise patients to maintain adequate hydration [see *Adverse Reactions (6.1)*].

Active ingredient made in China.

Distributed and Marketed by:

Pharmacyclics LLC

Sunnyvale, CA USA 94085

and

Marketed by:

Janssen Biotech, Inc.

Horsham, PA USA 19044

Patent <http://www.imbruvica.com>

IMBRUVICA[®] is a registered trademark owned by Pharmacyclics LLC

© Pharmacyclics LLC 2017

© Janssen Biotech, Inc. 2017

Patient Information
IMBRUVICA (im-BRU-vih-kuh)
(ibrutinib)
capsules

What is IMBRUVICA?

IMBRUVICA is a prescription medicine used to treat adults with:

- Mantle cell lymphoma (MCL) who have received at least one prior treatment
- Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL)
- Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) with 17p deletion
- Waldenström's macroglobulinemia (WM)
- Marginal zone lymphoma (MZL) who require a medicine by mouth or injection (systemic therapy) and have received a certain type of prior treatment
- Chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy

It is not known if IMBRUVICA is safe and effective in children.

Before taking IMBRUVICA, tell your healthcare provider about all of your medical conditions, including if you:

- have had recent surgery or plan to have surgery. Your healthcare provider may stop IMBRUVICA for any planned medical, surgical, or dental procedure
- have bleeding problems
- have or had heart rhythm problems, smoke, or have a medical condition that increases your risk of heart disease, such as high blood pressure, high cholesterol, or diabetes
- have an infection
- have liver problems
- are pregnant or plan to become pregnant. IMBRUVICA can harm your unborn baby. If you are able to become pregnant, your healthcare provider will do a pregnancy test before starting treatment with IMBRUVICA.
 - **Females** should not become pregnant during treatment and for 1 month after the last dose of IMBRUVICA.
 - **Males** should avoid getting female partners pregnant during treatment and for 1 month after the last dose of IMBRUVICA.
- are breastfeeding or plan to breastfeed. You and your healthcare provider should decide if you will take IMBRUVICA or breastfeed.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking IMBRUVICA with certain other medicines may affect how IMBRUVICA works and can cause side effects.

How should I take IMBRUVICA?

- Take IMBRUVICA exactly as your healthcare provider tells you to take it.
- Take IMBRUVICA 1 time a day.
- Swallow IMBRUVICA capsules whole with a glass of water. Do not open, break, or chew IMBRUVICA capsules.
- Take IMBRUVICA at about the same time each day.
- If you miss a dose of IMBRUVICA take it as soon as you remember on the same day. Take your next dose of IMBRUVICA at your regular time on the next day. Do not take 2 doses of IMBRUVICA on the same day to make up for a missed dose.
- If you take too much IMBRUVICA call your healthcare provider or go to the nearest hospital emergency room right away.

What should I avoid while taking IMBRUVICA?

- You should not drink grapefruit juice, eat grapefruit, or eat Seville oranges (often used in marmalades) during treatment with IMBRUVICA. These products may increase the amount of IMBRUVICA in your blood.

What are the possible side effects of IMBRUVICA?

IMBRUVICA may cause serious side effects, including:

- **Bleeding problems (hemorrhage) are common** during treatment with IMBRUVICA, and can also be serious and may lead to death. Your risk of bleeding may increase if you are also taking a blood thinner medicine. Tell your healthcare provider if you have any signs of bleeding, including:
 - blood in your stools or black stools (looks like tar)
 - pink or brown urine
 - unexpected bleeding, or bleeding that is severe or that you cannot control
 - vomit blood or vomit looks like coffee grounds
 - cough up blood or blood clots
 - increased bruising
 - dizziness
 - weakness
 - confusion
 - change in your speech
 - headache that lasts a long time

- **Infections** can happen during treatment with IMBRUVICA. These infections can be serious and may lead to death. Tell your healthcare provider right away if you have fever, chills, weakness, confusion, or other signs or symptoms of an infection during treatment with IMBRUVICA.
- **Decrease in blood cell counts.** Decreased blood counts (white blood cells, platelets, and red blood cells) are common with IMBRUVICA, but can also be severe. Your healthcare provider should do monthly blood tests to check your blood counts.
- **Heart rhythm problems (atrial fibrillation and atrial flutter).** Heart rhythm problems have happened in people treated with IMBRUVICA, especially in people who have an increased risk for heart disease, have an infection, or who have had heart rhythm problems in the past. Tell your healthcare provider if you get any symptoms of heart rhythm problems, such as feeling as if your heart is beating fast and irregular, lightheadedness, dizziness, shortness of breath, chest discomfort, or you faint.
- **High blood pressure (hypertension).** New or worsening high blood pressure has happened in people treated with IMBRUVICA. Your healthcare provider may start you on blood pressure medicine or change current medicines to treat your blood pressure.
- **Second primary cancers.** New cancers have happened during treatment with IMBRUVICA, including cancers of the skin or other organs.
- **Tumor lysis syndrome (TLS).** TLS is caused by the fast breakdown of cancer cells. TLS can cause kidney failure and the need for dialysis treatment, abnormal heart rhythm, seizure, and sometimes death. Your healthcare provider may do blood tests to check you for TLS.

The most common side effects of IMBRUVICA in adults with MCL, CLL/SLL, WM, and MZL include:

- | | |
|------------------------|-------------|
| • diarrhea | • bruising |
| • muscle and bone pain | • tiredness |
| • rash | • fever |
| • nausea | |

The most common side effects of IMBRUVICA in adults with cGVHD include:

- | | | |
|-------------|----------------------------|-------------|
| • tiredness | • muscle spasms | • pneumonia |
| • bruising | • mouth sores (stomatitis) | |
| • diarrhea | • nausea | |

Diarrhea is a common side effect in people who take IMBRUVICA. Drink plenty of fluids during treatment with IMBRUVICA to help reduce your risk of losing too much fluid (dehydration) due to diarrhea. Tell your healthcare provider if you have diarrhea that does not go away.

These are not all the possible side effects of IMBRUVICA.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How should I store IMBRUVICA?

- Store IMBRUVICA at room temperature between 68°F to 77°F (20°C to 25°C).
- Keep IMBRUVICA in the original container with the lid tightly closed.

Keep IMBRUVICA and all medicines out of the reach of children.

General information about the safe and effective use of IMBRUVICA

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use IMBRUVICA for a condition for which it was not prescribed. Do not give IMBRUVICA to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about IMBRUVICA that is written for health professionals.

What are the ingredients in IMBRUVICA?

Active ingredient: ibrutinib

Inactive ingredients: croscarmellose sodium, magnesium stearate, microcrystalline cellulose, sodium lauryl sulfate.

The capsule shell contains gelatin, titanium dioxide, and black ink.

Distributed and Marketed by: Pharcytics LLC Sunnyvale, CA USA 94085

Marketed by: Janssen Biotech, Inc. Horsham, PA USA 19044. For more information call 1-877-877-3536.

© Pharcytics LLC 2017

© Janssen Biotech, Inc. 2017

This Patient Information has been approved by the U.S. Food and Drug Administration.

Revised: 08/2017